Elranatamab in R/R Multiple Myeloma

Conditions

• Multiple Myeloma
• Refractory Multiple Myeloma
• Relapse Multiple Myeloma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Elranatamab — DRUG
  subcutaneous (under the skin) injection

Study Details

This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.

Key Dates

Start date

Mar 8, 2024

Status verified

Mar 2026

Primary completion

Aug 1, 2026

Completion

Dec 1, 2028

Study Design

Enrollment

32 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Elranatamab
  Elranatamab subcutaneous injections at pre-determined doses, administered at the following timepoints during each 28-day cycle: Cycle 1: Days 1, 4, 8, 15, and 22; Cycle 2: Days 1, 8, 15, and 22 ; Cycles 3-6: Days 1 and 15

Primary Outcome Measure

Complete Response (CR) rate or stringent CR (sCR) post consolidation therapy [ Time Frame: The time from start of treatment to first date that progressive disease is objectively documented or death due to any cause, for up to 5 years. Participants without events reported are censored at the last disease evaluation. ]

Central Contacts

• Noopur Raje, MD
  617-726-0711
  [email protected]

Locations (3)

Find similar trials in Boston, MA

Related Studies

• Collection of Samples and Clinical Data From Patients With Amyloid Diseases
  Recruiting · Boston Medical Center · Boston, Massachusetts
• Integrated Cancer Repository for Cancer Research
  Recruiting · University of Nebraska · Greenwood Village, Colorado
• Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
  Recruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
• Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
  PHASE1 · Recruiting · Newave Pharmaceutical Inc · Chicago, Illinois